普拉克索联合多巴丝肼片治疗晚期帕金森病的效果观察

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets in the treatment of advanced Parkinson′s disease.Methods A total of 80 patients with advanced Parkinson′s disease who were admitted to our hospital from June 2016 to June 2017 were selected as the study subjects.According to the random number table method,they were divided into observation group (40 cases)and control group (40 cases).The control group was treated with Levodopa and Benserazide Hydrochloride Tablets alone,and the observation group was given Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets.The control rate of advanced Parkinson′s disease,the simple intelligent mental state examination scale scores,the Hamilton depression scale scores,and the Parkinson′s comprehensive scale scores before and after the intervention,expression ability scores,the memory scores,the reading and understanding scores,time concept scores after treatment and incidence of adverse drug reactions were compared between two groups.Results The control rate of Parkinson′s disease in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P＜0.05).There were no significant differences in the simple intelligent mental state examination scale scores,the Hamilton depression scale scores,and the Parkinson′s comprehensive scale scores before intervention between two groups(P＞0.05).The scores of the simple intelligent mental state examination scale after the intervention in two groups were higher than those before the intervention,the scores of the Hamilton depression scale and the Parkinson′s comprehensive scale were lower than those before the intervention,and the differences were statistically significant(P＜0.05).The scores of the simple intelligent mental state examination scale after the intervention in the observation group were higher than those in the control group,the scores of the Hamilton depression scale and the Parkinson′s comprehensive scale were lower than those in the control group,and the differences were statistically significant(P＜0.05).The scores of expression ability,memory,reading and understanding,and time concept of the observation group were higher than those of the control group,and the differences were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between two groups(P＞0.05).Conclusion Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets has a definite effect in the treatment of advanced Parkinson′s disease.It can effectively improve the clinical symptoms,improve the patients′cognitive function,depressive mood and mental state,and has no serious adverse reactions,which is safe and effective and worthy of promotion and application.

Key words： Levodopa and Benserazide Hydrochloride Tablets Pramipexole Advance Parkinson&prime s disease Application effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I25/137

[2]	彭文君.盐酸普拉克索联合美多巴治疗帕金森病的临床疗效[J].中国现代医生，2012，50（5）：58-59.
[1]	Giduthuri SB，Sundaram S，Belathur SM，et al.A novel PBLMcRBFN-RFE approach for identification of critical brain regions responsible for Parkinson′s disease[J].Expert Syst Appl，2014，41（2）：478-488.
[3]	叶华，王耀光，金哲如，等.普拉克索联用美多巴治疗原发性帕金森病的疗效观察[J].现代实用医学，2015，27（10）：1307-1309.
[4]	胡月丹.美多巴联合盐酸普拉克索治疗老年帕金森病的疗效及对运动功能的影响[J].中国老年学杂志，2015，35（23）：6798-6800.
[5]	吴艳，杜娟，任义胜，等.美多巴联合恩他卡朋治疗对帕金森病患者血浆同型半胱氨酸水平的影响[J].临床神经病学杂志，2016，29（5）：333-335.
[6]	Mauro C，Leonardo V，Sara S，et al.Prediction of the Unified Parkinson′s Disease Rating Scale assessment using a genetic programming system with geometric semantic genetic operators[J].Expert Syst Appl，2014，41（10）：4608-4616.
[7]	吴艳，王小姗，张丽，等.美多巴对帕金森病患者抗氧化效应的研究[J].临床神经病学杂志，2015，28（6）：431-433.
[8]	王永久，程焱.多巴丝肼对帕金森病患者血浆同型半胱氨酸和脑血流动力学的影响[J].中国老年学杂志，2012，32（3）：486-487.
[9]	Lones MA， Smith SL，Alty JE，et al.Evolving classifiers to recognize the movement characteristics of Parkinson′s disease patients[J].IEEE Trans Evol Comput，2014，18（4）：559-576.
[10]	于苏文，郑秀琴，陈红霞，等.恩他卡朋添加治疗对药效减退的帕金森病患者的疗效观察[J].临床神经病学杂志，2010，23（1）：70-72.
[11]	王晓平，罗永杰，吴景芬，等.多巴丝肼联合电针对老年帕金森病患者血清白细胞介素-1β、胱抑素C及血清离子水平的影响[J].中国老年学杂志，2016，36（17）：4301-4303.
[12]	Hariharan M，Polat K，Sindhu R，et al.A new hybrid intelligent system for accurate detection of Parkinson′s disease[J].Comput Methods Programs Biomed，2014，113（3）：804-913.
[13]	刘书芳，汪琳.美多巴联合普拉克索治疗帕金森病的临床效果观察[J].中国实用医药，2016，11（25）：141-142.
[14]	林秀艳.美多巴单用及与多巴胺受体激动剂合用治疗帕金森病的临床疗效观察[J].中国现代药物应用，2016，10（7）：121-122.
[15]	王雷.美多巴联合普拉克索治疗帕金森病的效果[J].中国当代医药，2018，25（9）：93-96.
[16]	叶华，杨晓凯，王耀光，等.依达拉奉治疗帕金森病运动功能波动的疗效观察[J].中国现代医生，2017，55（10）：109-112.
[17]	解建国，王妍妮，XIE JG，等.左旋多巴联合恩他卡朋对帕金森病患者血清IL-1β及Cys-C的影响[J].西部医学，2017（6）：791-794.
[18]	姚胜旗，陆学胜，许敏，等.盐酸美金刚联合用药治疗帕金森痴呆的疗效分析[J].临床和实验医学杂志，2016，15（9）：875-878.
[19]	杨醒鸿，苏玉蓉，李欣.美多芭联合盐酸普拉克索治疗帕金森病的临床研究[J].中国当代医药，2017，24（35）：125-127.